Short snapshot of 21 SP's status as of May 2013

1. 1
21 SP, Inc.
Overview:
 21 SP’s Mission: About 100,000 people die each year in the US from pharmaceuticals prescribed “properly” and countless
millions are wasted due to the current treatment approach of trial-and-error. 21 SP’s mission is to improve clinical therapeutic
decision making in order to reduce unnecessary adverse drug reactions and improve drug efficacy, which will save health care
expense due to the reduction of trial-and-error medicine.
 Product/service:Products are clinical treatment guides, informed by pharmacogenetics (PGx) and other recent clinical
research, for use in various therapeutic areas. Products are intended to bridge the gap between research and the clinic and will
be of value in guiding physicians whether or not they choose to use PGx tests.
 Intellectual Property: A provisional patent was filed on 21 SP’s first product, WarPhgx.
 Total Available U.S. Market: $27M (market for physicians only) for the initial three products. 21 SP has plans to expand
substantially into other markets using a building block approach. Initial products will be components of additional more
sophisticated products. The market over time, which will include MDs, nurse practitioners, registered nurses and pharmacists,
will be much larger than the initial $27M US market.
 Teamsize: One currently full-time.
 Corporate location and contact information: 21 SP, Inc., 18 Silva Ave., Millbrae, CA, 94030. jshomaker@21spinc.com, (650)
455-7261, www.21spinc.com.
Founder:
 Founder/President: Jeff Shomaker. Held business positions (e.g., Finance and Strategic Planning) at Elan Pharmaceuticals
(previously Athena Neurosciences) and DrugAbuse Sciences. Held technical computer programmer positions at Hewlett-
Packard & Texas Instruments. Holds an MA in Business Economics (UC Santa Barbara) and a BS & MS in Management
Information Systems (Colorado State University). In addition, has completed the equivalent of one-year’s full-time study in
biology & pharmacology (UC Berkeley & UC Santa Cruz).

2. 2
21 SP, Inc. (cont.)
Stage of development:
 R&D Stage Complete: 21 SP has developed a R&D clinical decision support system (DSS) incorporating fourteen disease
areas (eg, epilepsy) and thirty-four drugs. After the physician completes the diagnosis, the system considers age, genetics,
physiological state, pathological state and drug interactions. The DSS demonstrates how PGx can be incorporated into the
clinical decision-making process to significantly improve efficacy and reduce adverse drug reactions. This proprietary system
and DB will be the source of future products.
 First Commercial Product: 21 SP has completed the development of its first product, which is a specialized system for heart
disease. The system, which runs on android-based smart phones and tablets, has 110 different displays and steps the
physician through the clinical decision-making process when there is significant complexity. The product is for the drug warfarin,
which is used for patients needing anticoagulation when they have conditions such as atrial fibrillation, deep vein thrombosis,
and myocardial infarctions (heart attacks). The product is currently available as a free download on the Google Play market and
is called WarPhGx. See 21 SP’s website at www.21spinc.com for a direct link to the product download.
 Further Commercial Product Development: Further products are expected to be launched on at least an annual basis using a
modular building block approach. Ten total products, which will become increasingly sophisticated over time, are currently
planned. In addition, 21 SP has plans to expand into other markets related to the company’s core strengths, which are using
mobile technology to improve clinical decision making, especially when there is significant complexity.